DHODH and glioblastoma: Recent studies have illustrated that DHODH inhibitors are more effective against malignancies with specific genetic context, such as melanomas carrying BRAF (V600E) mutation [89] and glioblastoma stem cells [25] and breast cancer with PTEN deletion [25, 29] and pancreatic cancer with KRAS mutation [63].